POMALIDOMIDE (POM) plus LOW-DOSE DEXAMETHASONE (LODEX) AFTER SECOND-LINE LENALIDOMIDE (LEN)-BASED TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PROGRESSION-FREE SURVIVAL ANALYSIS

被引：0

作者：

Siegel, D. S. ^{[1
]}

Schiller, G. J. ^{[2
]}

Song, K. ^{[3
]}

Agajanian, R. ^{[4
]}

Stockerl-Goldstein, K. ^{[5
]}

Kaya, H. ^{[6
]}

Sebag, M. ^{[7
]}

Reu, F. J. ^{[8
]}

Malek, E. ^{[9
]}

Talamo, G. ^{[10
]}

Mouro, J. ^{[11
]}

Chung, W. ^{[11
]}

Srinivasan, S. ^{[11
]}

Qian, M. ^{[11
]}

Rizvi, S. ^{[11
]}

Thakurta, A. ^{[11
]}

Bahlis, N. J. ^{[12
]}

机构：

[1] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[2] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[3] Vancouver Gen Hosp, Vancouver, BC, Canada

[4] Oncol Inst Hope & Innovat, Downey, CA USA

[5] Washington Univ, Sch Med, St Louis, MO USA

[6] Canc Care Northwest, Spokane, WA USA

[7] McGill Univ, Ctr Hlth, Montreal, PQ, Canada

[8] Cleveland Clin, Cleveland, OH 44106 USA

[9] Univ Hosp Cleveland, Case Med Ctr, Cleveland, OH 44106 USA

[10] Penn State Hershey Canc Inst, Hershey, PA USA

[11] Celgene Corp, Summit, NJ USA

[12] Univ Calgary, Calgary, AB, Canada

来源：

HAEMATOLOGICA | 2017年 / 102卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

E1248

引用

页码：511 / 511

页数：1

共 50 条

[41] Pomalidomide plus Bortezomib plus Low-Dose Dexamethasone Vs Bortezomib plus Low-Dose Dexamethasone As Second-Line Treatment in Patients with Lenalidomide-Pretreated Multiple Myeloma: A Subgroup Analysis of the Phase 3 Optimismm Trial
Dimopoulos, Meletios A.
Weisel, Katja
Moreau, Philippe
Anderson, Larry
White, Darrell J.
San-Miguel, Jesus F.
Sonneveld, Pieter
Engelhardt, Monika
Jenner, Matthew W.
Corso, Alessandro
Duerig, Jan
Pavic, Michel
Salomo, Morten
Yu, Xin
Tuong Vi Nguyen
Bensmaine, Amine
Peluso, Teresa
Zaki, Mohamed
Richardson, Paul
BLOOD, 2018, 132
[42] Final Analysis, Cytogenetics, Long-Term Treatment, and Long-Term Survival In MM-003, A Phase 3 Study Comparing Pomalidomide plus Low-Dose Dexamethasone (POM plus LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM)
Dimopoulos, Meletios A.
Weisel, Katja
Song, Kevin W.
Delforge, Michel
Karlin, Lionel
Goldschmidt, Hartmut
Moreau, Philippe
Banos, Anne
Oriol, Albert
Garderet, Laurent
Cavo, Michele
Ivanova, Valentina
Alegre, Adrian
Lopez, Joaquin Martinez
Chen, Christine I.
Spencer, Andrew
Knop, Stefan
Bahlis, Nizar J.
Renner, Christoph
Yu, Xin
Hong, Kevin
Sternas, Lars
Jacques, Christian
Zaki, Mohamed H.
San Miguel, Jesus F.
BLOOD, 2013, 122 (21)
[43] Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): final overall survival analysis
Richardson, Paul
Perrot, Aurore
San-Miguel, Jesus
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey Shang-Yi
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Malinge, Laure
Dubin, Franck
Morisse, Mony
Anderson, Kenneth
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S32 - S32
[44] Patient Outcomes By Prior Therapies and Depth of Response: Analysis of MM-003, a Phase 3 Study Comparing Pomalidomide plus Low-Dose Dexamethasone (POM plus LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM)
San Miguel, Jesus F.
Weisel, Katja
Song, Kevin W.
Delforge, Michel
Karlin, Lionel
Goldschmidt, Hartmut
Moreau, Philippe
Banos, Anne
Oriol, Albert
Garderet, Laurent
Cavo, Michele
Ivanova, Valentina
Alegre, Adrian
Martinez-Lopez, Joaquin
Chen, Christine I.
Renner, Christoph
Bahlis, Nizar J.
Yu, Xin
Teasdale, Terri
Sternas, Lars
Jacques, Christian
Zaki, Mohamed H.
Dimopoulos, Meletios A.
BLOOD, 2013, 122 (21)
[45] Lenalidomide versus lenalidomide plus dexamethasone prolonged treatment after second-line lenalidomide plus dexamethasone induction in multiple myeloma
Lund, Johan
Gruber, Astrid
Lauri, Birgitta
Duru, Adil Doganay
Blimark, Cecilie
Swedin, Agneta
Hansson, Markus
Forsberg, Karin
Ahlberg, Lucia
Carlsson, Conny
Waage, Anders
Gimsing, Peter
Vangsted, Annette Juul
Frolund, Ulf
Holmberg, Erik
Gahrton, Gosta
Alici, Evren
Hardling, Mats
Mellqvist, Ulf-Henrik
Nahi, Hareth
CANCER MEDICINE, 2018, 7 (06): : 2256 - 2268
[46] Pomalidomide (CC4047) plus Low-Dose Dexamethasone (Pom/Dex) as Therapy for Relapsed Multiple Myeloma
Lacy, Martha Q.
Hayman, Suzanne R.
Gertz, Morie A.
Dispenzieri, Angela
Zeldenrust, Stephen R.
Kumar, Shaji
Greipp, Philip R.
Lust, John A.
Russell, Stephen J.
Buadi, Francis
Kyle, Robert A.
Fonseca, Rafael
Bergsagel, P. Leif
Roy, Vivek
Mikhael, Joseph R.
Stewart, A. Keith
Allred, Jacob B.
Laumann, Kristina
Thompson, Melanie
Mandrekar, Sumithra J.
Rajkumar, S. Vincent
Dingli, David
Reeder, Craig
CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S46 - S47
[47] Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023
San Miguel, Jesus
Mateos, Maria-Victoria
Shah, Jatin J.
Ocio, Enrique M.
Rodriguez-Otero, Paula
Reece, Donna
Munshi, Nikhil C.
Avigan, David
Ge, Yang
Balakumaran, Arun
Marinello, Patricia
Orlowski, Robert Z.
Siegel, David
BLOOD, 2015, 126 (23)
[48] MM-007: A phase 3 trial comparing the efficacy and safety of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) versus BORT and LoDEX (VD) in subjects with relapsed or refractory multiple myeloma (RRMM).
Richardson, Paul G.
Bensmaine, Amine
Doerr, Thomas
Wang, Jianming
Zaki, Mohamed H.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[49] Analysis of Patient (Pt) Outcomes By Prior Treatment and Depth of Response in Stratus (MM-010), a Phase 3b Study of Pomalidomide plus Low-Dose Dexamethasone (POM plus LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Moreau, Philippe
Palumbo, Antonio
Corradini, Paolo
Cavo, Michele
Delforge, Michel
Weisel, Katja C.
Ocio, Enrique M.
Cafro, Annamaria
Rollig, Christoph
Knop, Stefan
de Arriba, Felipe
Simcock, Mathew
Miller, Neil
Slaughter, Ana
Watkins, Latisha
Herring, Jennifer
Biyukov, Tsvetan
Peluso, Teresa
Zaki, Mohamed H.
Dimopoulos, Meletios A.
BLOOD, 2015, 126 (23)
[50] Adverse event (AE) management in patients (pts) with relapsed and refractory multiple myeloma (RRMM) taking pomalidomide (POM) plus low dose-dexamethasone (LoDEX): A pooled analysis from 3 clinical trials.
Moreau, Philippe
Dimopoulos, Meletios A.
Richardson, Paul G.
Siegel, David Samuel DiCapua
Palumbo, Antonio
Cavo, Michele
Corradini, Paolo
Weisel, Katja
Delforge, Michel
O'Gorman, Peter
Song, Kevin W.
Sternas, Lars Axel
Peluso, Teresa
Hong, Kevin
Herring, Jennifer
Yu, Xin
Zaki, Mohamed H.
Miguel, Jesus San
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 2 3 4 5 →